GlassScriptPhysician profile
John David Hanna
NPI 1154944569
$4,900.87
in general payments reported to CMS, 2019-2025
32 companies · $4,528 in 2025
The $4,528 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.55 · 2024: $352 · 2025: $4,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,354 · Consulting Fee: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,354.32 |
| Consulting Fee | $1,525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,684.39 | 2024-2025 | |
| Abbvie INC. | $542.88 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $291.78 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $242.19 | 2025 | Ultomiris |
| Neurelis, INC. | $239.07 | 2024-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $228.40 | 2024-2025 | Nuplazid |
| Lundbeck LLC | $225.53 | 2024-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $172.41 | 2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $168.49 | 2024-2025 | Ingrezza |
| Csl Behring | $137.14 | 2025 | Hizentra |
| Argenx US, INC. | $106.04 | 2024-2025 | Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $101.82 | 2025 | |
| Amgen INC. | $86.10 | 2025 | Uplizna |
| Grifols USA, LLC | $84.98 | 2025 | Gamunex-C |
| Eisai INC. | $65.43 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $60.53 | 2025 | Qutenza |
| Axsome Therapeutics, INC. | $48.16 | 2025 | Symbravo |
| Genzyme Corporation | $42.84 | 2025 | |
| Emd Serono, INC. | $40.86 | 2025 | |
| Novo Nordisk INC | $39.33 | 2025 | Rybelsus, Ozempic |
| Vanda Pharmaceuticals INC. | $38.39 | 2025 | Ponvory |
| Mallinckrodt Hospital Products INC. | $35.22 | 2025 | Acthar |
| Cycle Pharmaceuticals INC | $33.33 | 2024-2025 | Tascenso Odt |
| Celgene Corporation | $30.44 | 2025 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $24.27 | 2025 | Rexulti |
| Microvention, INC. | $21.55 | 2022 | |
| Biogen, INC. | $21.35 | 2024 | Vumerity |
| Impel Pharmaceuticals LLC | $20.71 | 2025 | Trudhesa |
| Genentech USA, INC. | $18.41 | 2024 | Ocrevus Zunovo, Ocrevus |
| Shield Therapeutics INC | $17.29 | 2025 | |
| Merck Sharp & Dohme LLC | $16.61 | 2025 | Lagevrio |
| Lilly USA, LLC | $14.93 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.